• LL-37 and Mimetics: Differential Antibiofilm Actions via Cry

  2026-06-29

  This study systematically evaluates the biocidal and antibiofilm properties of human host defense peptide LL-37 and its truncated mimetics KE-18 and KR-12 against major pathogens. By leveraging both crystal violet and XTT assays, the research uncovers nuanced differences in antimicrobial and biofilm-prevention activities, informing the design of next-generation peptide therapeutics.

• Angiotensin (1-7): Mechanisms, Benchmarks, and Experimental

  2026-06-29

  Angiotensin (1-7) is an endogenous heptapeptide hormone with validated anti-fibrotic and anti-inflammatory effects. Its actions are mediated via Mas receptor engagement and modulation of PI3K/AKT and ERK pathways. High-purity Angiotensin (1-7) from APExBIO supports reproducible research in metabolic, fibrotic, and neuroprotective domains.

• ATP Solution for mRNA-LNP Bladder Cancer Assays: Protocols &

  2026-06-28

  ATP Solution (100 mM) empowers high-fidelity kinase, in vitro transcription, and phosphorylation workflows essential for next-generation mRNA-LNP therapeutics. This guide distills direct protocol enhancements, troubleshooting strategies, and experimental insights tailored for sensitive bladder cancer research and beyond.

• 8-Chloroadenosine: Advanced Workflows for RNA Metabolism Stu

  2026-06-27

  8-Chloroadenosine stands out as a high-purity nucleoside analog for precise inhibition of RNA synthesis and advanced study of transcriptional regulation in cancer research. This guide delivers actionable, evidence-based workflows and troubleshooting strategies for maximizing experimental impact in RNA metabolism and non-coding RNA mechanistic assays.

• Sulfo-NHS-Biotin: Optimizing Protein Labeling for Cell Surfa

  2026-06-26

  Sulfo-NHS-Biotin enables precise, water-based labeling of cell surface proteins—ideal for advanced affinity chromatography and immunoprecipitation workflows. Explore best practices, troubleshooting, and innovation inspired by recent high-throughput screening studies, ensuring robust and reproducible protein biotinylation.

• Nigericin Sodium Salt: Potassium Ionophore Workflows Unlocke

  2026-06-26

  Nigericin sodium salt delivers precision ion transport and cytoplasmic pH control, setting new standards for reproducible platelet aggregation, toxicology, and metabolic studies. Learn how advanced workflows, troubleshooting strategies, and data-driven parameters using APExBIO’s high-purity reagent can elevate your experimental outcomes.

• Hydroxychloroquine Sulfate for Autoimmune Disease Research W

  2026-06-25

  Hydroxychloroquine Sulfate (SKU B4874) is used to inhibit autophagy and TLR7/9 signaling in models of autoimmune disease, including systemic lupus erythematosus and rheumatoid arthritis. It should be utilized in aqueous-based, short-term protocols and is not suitable for workflows requiring organic solvents or long-term solution storage.

• Necrostatin-1: Strategic RIP1 Kinase Inhibition in Translati

  2026-06-25

  Necrostatin-1 (Nec-1) is transforming translational research by enabling precise modulation of necroptotic cell death through selective RIP1 kinase inhibition. This article explores the mechanistic foundations, experimental best practices, and new clinical opportunities for leveraging Nec-1 in inflammatory and tissue injury models. Drawing on recent advances in Crohn’s disease pathogenesis and referencing both primary literature and domain-leading protocols, we guide researchers beyond standard product usage toward strategic, biomarker-driven innovation.

• OSMI-1: A Benchmark O-GlcNAc Transferase Inhibitor for Preci

  2026-06-24

  OSMI-1, a potent O-GlcNAc transferase inhibitor, empowers researchers to dissect protein O-GlcNAcylation with high specificity and reproducibility. Its use is redefining workflows in ferroptosis and trophoblast syncytialization research, especially in translational preeclampsia models.

• 3-Aminobenzamide (PARP-IN-1): Precision Inhibition for Advan

  2026-06-23

  3-Aminobenzamide (PARP-IN-1) empowers researchers with highly selective, nanomolar-range PARP inhibition for disease modeling and cell stress assays. Leverage its robust performance in oxidative injury, endothelial function, and diabetic nephropathy workflows—plus actionable troubleshooting tips for reproducible results.

• Z-IETD-FMK: Caspase-8 Inhibition in Apoptosis and T Cell Res

  2026-06-23

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) enables precise, reproducible inhibition of caspase-8, empowering advanced apoptosis, NF-κB signaling, and immune cell activation assays. This guide translates new functional genomics and workflow innovations into actionable protocols, troubleshooting, and strategic insights for immune and cancer research.

• Spliceosome, DNA Repair & Rucaparib: Expanding PARP Inhibito

  2026-06-22

  Recent discoveries in spliceosome regulation and DNA repair have redefined the landscape for PARP inhibitor research. Leveraging the potent PARP1 inhibitor Rucaparib (AG-014699), translational scientists now have unprecedented opportunities to interrogate radiosensitization, synthetic lethality, and combinatorial strategies in cancer models beyond BRCA deficiency. This article synthesizes mechanistic insights with actionable guidance, drawing from new evidence in hepatocellular carcinoma and integrating advanced experimental design considerations.

• Gepotidacin (GSK2140944): Mechanistic Innovation and Assay D

  2026-06-22

  Explore Gepotidacin (GSK2140944), a groundbreaking bacterial DNA gyrase inhibitor, with an in-depth analysis of its unique mechanism, assay optimization, and implications for antibiotic resistance research. This article delivers advanced perspectives for scientific teams seeking to refine antibacterial workflows.

• Dissecting Pain Circuits with nor-Binaltorphimine Dihydrochl

  2026-06-21

  This article explores the mechanistic and translational significance of nor-Binaltorphimine dihydrochloride, a selective κ-opioid receptor antagonist, in advancing pain modulation research. Integrating recent circuit-level discoveries, practical guidance, and strategic foresight, we provide a blueprint for translational researchers navigating the complexities of opioid receptor signaling.

• Selective Nanomolar IRAP Inhibitors from Bestatin Derivative

  2026-06-20

  This study introduces a new class of α-hydroxy-β-amino acid derivatives inspired by Bestatin, yielding cell-active, nanomolar-selective inhibitors of insulin-regulated aminopeptidase (IRAP). These findings offer valuable chemical tools for dissecting IRAP’s role in immunity and cancer, and advance the structure-based design of potent, selective aminopeptidase inhibitors.

451 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page